Literature DB >> 17684737

What is the true risk of a pharmacokinetic drug-drug interaction?

Uwe Fuhr.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17684737     DOI： 10.1007/s00228-007-0357-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  9 in total

1.  Polypharmacy and hospitalization among older home care patients.

Authors:  J H Flaherty; H M Perry; G S Lynchard; J E Morley
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2000-10       Impact factor: 6.053

2.  Voriconazole and fluconazole increase the exposure to oral diazepam.

Authors:  Teijo I Saari; Kari Laine; Leif Bertilsson; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2007-08-04       Impact factor: 2.953

3.  Lack of pharmacokinetic interaction as an equivalence problem.

Authors:  V W Steinijans; M Hartmann; R Huber; H W Radtke
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1991-08

4.  Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam.

Authors:  J T Backman; J S Wang; X Wen; K T Kivistö; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  1999-10       Impact factor: 6.875

5.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors:  John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal:  N Engl J Med       Date:  2005-03-08       Impact factor: 91.245

6.  Gemfibrozil greatly increases plasma concentrations of cerivastatin.

Authors:  Janne T Backman; Carl Kyrklund; Mikko Neuvonen; Pertti J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

7.  Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.

Authors:  Nils von Hentig; Brenda Dauer; Annette Haberl; Stefan Klauke; Thomas Lutz; Schlomo Staszewski; Sebastian Harder
Journal:  Eur J Clin Pharmacol       Date:  2007-07-31       Impact factor: 2.953

8.  Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia.

Authors:  L Andrén; A Andreasson; R Eggertsen
Journal:  Eur J Clin Pharmacol       Date:  2007-08-15       Impact factor: 2.953

9.  Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.

Authors:  J W Nawrocki; S R Weiss; M H Davidson; D L Sprecher; S L Schwartz; P J Lupien; P H Jones; H E Haber; D M Black
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311
  9 in total
  1 in total

1.  Improvement in the handling of drug-drug interactions.

Authors:  Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2008-01-03       Impact factor: 2.953
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.